Any current/future new fundraising through debt or equity?

The transcript does not mention any current or future fundraising plans through debt or equity. The discussion primarily focuses on business growth, revenue, margin guidance, capacity expansion, and market penetration. Capex plans include Rs. 2.9 Crores for renovation, Rs. 8 Crores for R&D, and Rs. 8 Crores for expansion and modernization, funded through internal accruals or existing resources (not explicitly stated). No details about raising funds via debt or equity were provided during this call.

Future growth expectations in sales/revenue/volumes?

The company expects to maintain the same topline growth and bottomline. Business is growing phenomenally at 30% to 40% year-on-year. Revenue for the current financial year is projected to cross Rs. 50 Crores. Growth drivers include high-quality production, good pricing, and marketing strategies. New product introductions from the operational R&D center will further boost growth. Expansion into international markets like the US, Brazil, Russia, and Saudi Arabia is a major focus. Export business is set to improve with new registrations and US FDA approvals. Increased digital marketing activities

Future growth expectations in earnings/operating earnings/profits/EPS?

Prevest DenPro aims to maintain strong topline growth and sustain the high EBITDA margin of around 40%, driven by specialized, value-added dental products with good pricing power. Revenue for FY2023 is expected to exceed Rs. 50 Crores with sustained profitability. The company plans robust international expansion, targeting entry into high-potential markets like the US, Brazil, and Russia, complementing existing exports to 85 countries. New capacity expansions and modernization are underway to meet growing demand efficiently. Operating margins are considered sustainable and expected to improve

Current/ Expected Orderbook/ Pending Orders?

The current order book of Prevest DenPro Limited is described as very comfortable with sufficient orders at present. The company is confident about continuing its growth without any disruption in the order inflow. There is no indication of lumpiness or delays in advanced payments from European countries despite economic instability, as payments are received on 100% advance basis. Saudi Arabian market is growing well with very good quantity of product orders, and the company expects much better business growth there in the coming times. The company is proactively expanding in international mark

IN US

Prevest DenproQ2 FY23Healthcare Equipment & Supplies

Prevest Denpro Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹378P/E: 21.4Market Cap: ₹458 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company expects to maintain the same topline growth and bottomline.
→Business is growing phenomenally at 30% to 40% year-on-year.
→Revenue for the current financial year is projected to cross Rs. 50 Crores.
→Growth drivers include high-quality production, good pricing, and marketing strategies.
→New product introductions from the operational R&D center will further boost growth.
→Expansion into international markets like the US, Brazil, Russia, and Saudi Arabia is a major focus.
→Export business is set to improve with new registrations and US FDA approvals.
→Increased digital marketing activities aim to connect with more dentists globally.
→Modernization and capacity expansion of manufacturing facilities support higher production volumes.
→The company is optimistic about sustained growth fueled by high-value specialized dental products.

Margin guidance

Category 3

→Prevest DenPro aims to maintain strong topline growth and sustain the high EBITDA margin of around 40%, driven by specialized, value-added dental products with good pricing power.
→Revenue for FY2023 is expected to exceed Rs. 50 Crores with sustained profitability.
→The company plans robust international expansion, targeting entry into high-potential markets like the US, Brazil, and Russia, complementing existing exports to 85 countries.
→New capacity expansions and modernization are underway to meet growing demand efficiently.
→Operating margins are considered sustainable and expected to improve with market diversification, including entry into markets with better margin profiles, like the US.
→R&D investments and launch of new product lines (disinfectant, oral hygiene, biomaterials) are expected to fuel growth.
→Quarterly accounting changes in employee costs may normalize expense recognition, improving clarity in future earnings.
→Overall, management is confident of continued double-digit growth in earnings and profits supported by strong fundamentals and business durability.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or future fundraising plans through debt or equity.
→The discussion primarily focuses on business growth, revenue, margin guidance, capacity expansion, and market penetration.
→Capex plans include Rs. 2.9 Crores for renovation, Rs. 8 Crores for R&D, and Rs. 8 Crores for expansion and modernization, funded through internal accruals or existing resources (not explicitly stated).
→No details about raising funds via debt or equity were provided during this call.

Order book

Yes

→The current order book of Prevest DenPro Limited is described as very comfortable with sufficient orders at present.
→The company is confident about continuing its growth without any disruption in the order inflow.
→There is no indication of lumpiness or delays in advanced payments from European countries despite economic instability, as payments are received on 100% advance basis.
→Saudi Arabian market is growing well with very good quantity of product orders, and the company expects much better business growth there in the coming times.
→The company is proactively expanding in international markets like US, Brazil, and Russia, and is engaging with potential buyers, suggesting a growing order pipeline.
→Overall, the business prospects and order inflow are stable and strong, supporting the company’s growth trajectory.

Capex plans

Yes

- Proposed capex for the financial year includes: - Rs. 2.9 Crores for renovation of existing plant and machinery. - Rs. 8 Crores for R&D facilities. - Rs. 8 Crores for expansion projects and modernization. - R&D center expected to be operational by Q2 FY2023. - New facilities for manufacturing disinfectant oral hygiene products, oral care products, and biomaterials are under advanced implementation, projected to be fully operational by Q3 FY2023, subject to regulatory approvals. - Modernization efforts ongoing with new high-speed machines installed, streamlining production and increasing capacity to cater to market demand over the next five years. - Total expanded capex made so far amounts to Rs. 11.04 Crores. - Additional modernization expenditure of around Rs. 1 Crore already spent, with another Rs. 1 Crore planned for upcoming months. Overall, key investments focus on capacity expansion, product innovation, and modernization to support growth.

How does Prevest Denpro rank vs peers in Healthcare Equipment & Supplies?

Pro feature

1Prevest Denpro

Rev 2Mar 3

See full Healthcare Equipment & Supplies sector rankings

Want more stocks like Prevest Denpro?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio